LLSC Corporate News

News

Read all The Leukemia & Lymphoma Society of Canada's press releases

Media Contact

Have media inquiries? Contact us between 9 a.m. and 5 p.m. ET, Monday through Friday.

 
Regina Kulikowski
Director Health Communications and Stakeholder Engagement

 

News Releases

Mark Barrenechea, OpenText CEO & CTO, to Chair Light The Night Walk in Toronto

Mark Barrenechea, OpenText CEO & CTO, and Leukemia Survivor to Chair Light The Night Walk in Toronto Global business leader renews pledge of support for The Leukemia & Lymphoma Society of Canada (LLSC) TORONTO, June 2, 2017 /CNW/ - It's National Cancer Survivor Day and Mark Barrenechea, CEO & CTO of OpenText, and a survivor of Acute Myeloid Leukemia has renewed his volu...

‘SpiderMable’ leads Ecole Lendrum in walk to fight against blood cancers

FOR IMMEDIATE RELEASE ‘SpiderMable’ leads students at the Ecole Lendrum school  in a special walk to support Canadians in the fight against blood cancers. Edmonton June 2, 2017, Toronto — In celebration of National Cancer Survivor Day on June 4th, Mable Tooke, aka SpiderMable, a well-known and much admired 9 year old Leukemia survivor from Edmonton is leading 200 of her fellow school mates as we...

Honoring Edmonton’s local heroes in the fight against childhood Leukemia!

For Immediate Release Honoring Edmonton’s local heroes in the fight against childhood Leukemia! Edmonton, May 4, 2017- The Leukemia and Lymphoma Society of Canada is hosting their Journey of Hope event today. The annual event celebrates blood cancer research advances and breakthroughs and recognizes survivors, health care providers and volunteers. Over 1,500 children are diagnosed with cancer in Canada eve...

LLSC congratulates the Celator team on receiving the BC Life Science Award

For Immediate Release   Toronto, April 20, 2017 – The Leukemia and Lymphoma Society of Canada is proud to congratulate Celator Pharmaceuticals Inc. in receiving the Deal of the Year Award at the 19th Annual Life Sciences BC Awards. The award comes on the heels of the successful development of Vyxeos, the first therapy to demonstrate statistically significant improvement in overall survival and induc...

Pages